Flagship Pioneering Secures $47M DoW Contract to Develop Next-Gen Medical Countermeasures
Flagship Pioneering has been awarded a first-of-its-kind, five-year contract worth up to $47 million by the Department of War (DoW) under its ONTARGET program. The initiative aims to accelerate the development of next-generation medical countermeasure technologies against evolving biological threats using Flagship's ecosystem of over 40 innovative companies and platforms in biotechnology and AI/machine learning. The contract represents a strategic shift for DoW, moving toward more agile partnerships with private-sector innovation leaders rather than traditional product-specific contracts. Initial projects will involve two Flagship-founded firms: Apriori Bio and Prologue Medicines. The agreement is managed by the Joint Science and Technology Office (JSTO) within the Chemical and Biological Defense Program. The ONTARGET program seeks to enhance medical countermeasure performance, speed development timelines, and improve response effectiveness for national defense preparedness. It focuses on broad-spectrum countermeasures, precision delivery technologies, toxin-neutralizing platforms, immune enhancement strategies, and AI integration in drug discovery.
Topics: biotechnology government contracts innovation ecosystem national security